Brief: Intellia Therapeutics Says One Dose Of NEX-Z Shows Durable TTR Reductions Of At Least 90% Through Three Years
25/09/2025 16:27
Sept 25 (Reuters) - Intellia Therapeutics Inc NTLA.O: INTELLIA THERAPEUTICS ANNOUNCES POSITIVE LONGER-TERM PHASE 1 DATA FOR NEXIGURAN ZICLUMERAN (NEX-Z) IN PATIENTS WITH HEREDITARY TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY INTELLIA THERAPEUTICS INC - ONE DOSE OF NEX-Z SHOWS DURABLE TTR REDUCTIONS OF AT LEAST 90% THROUGH THREE YEARS INTELLIA THERAPEUTICS INC - FAVORABLE SAFETY DATA WITH NO NEW DRUG-RELATED EVENTS INTELLIA THERAPEUTICS INC - PHASE 3 MAGNITUDE-2 TRIAL ENROLLMENT EXPECTED BY FIRST HALF 2026 Source text: ID:nGNXb5s3QB Further company coverage: NTLA.O (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)